ISSUE 1404
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir disoproxil fumarate (Stribild – Gilead) for treatment of HIV-1 infection in antiretroviral treament-naïve adults. Elvitegravir is the second INSTI to be approved by the FDA for use in HIV treatment; raltegravir (Isentress) was the first.1
FIRST-LINE TREATMENT OF HIV — Antiretroviral treatment regimens usually include a "backbone" and a "base". Recommended choices for first-line therapy of HIV infection, depending on the results of resistance testing, include a non-nucleoside reverse transcriptase inhibitor (NNRTI) such as efavirenz, a ritonavir-boosted protease inhibitor such as atazanavir, or an INSTI as the base,
... more
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1404c
Electronic, downloadable article - $45